Home > Result Summaries: Compounds > Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine

Result Summaries: Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine

Result Summaries for Combined Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio, Haemophilus influenzae Type b Conjugate Vaccine

GSK Study ID	Phase	Title	Summary (Download)
213503/044	Phase 4	Open study to assess the immunogenicity after two and three doses of GSK Bios’ Hib vaccine combined with GSK Bios’ DTPa-IPV vaccine given to Swedish infants in a 3, 5, 12 month schedule (0 citation(s))
213503/049	Phase 4	An open, multicentre, phase IV booster vaccination study to assess the immunogenicity and reactogenicity of GSKBiologicals combined Infanrix-IPV+Hib (DTPa-IPV/Hib) vaccine in healthy children aged 17 to 20 months whocompleted a three-dose primary vaccination course (2 citation(s))
213503/050	Phase 3	Study to evaluate safety and immunogenicity of a booster dose of DTPa-IPV/Hib at 18 months of age with GSK Biologicals DTPa-IPV/Hib compared to Aventis Pasteurs Pentacel, after an initial primary vaccination series administered at 2, 4, and6 months of age with Aventis Pasteurs Pentacel (1 citation(s))
347414/023	Phase 2	A phase II, single-blind, randomized, controlled study to evaluate the immunogenicity and safety of four different formulations of an investigational vaccination regimen when given intramuscularly as primary vaccination in infants at 3, 4 ½ and 6 months of age. (0 citation(s))

• Protocol Summaries
• Result Summaries
• GSK Prescription Medicines
• Contact GSK
• Glossary of Terms
• Terms and Conditions